Cargando…

Cystic brain metastases in ALK-rearranged non-small cell lung cancer

The central nervous system (CNS) is a common site of disease progression in patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK)-rearrangement treated with crizotinib. Cystic brain metastases (CBM) have been recently identified as one possible variant of this diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marta, Guilherme Nader, da Cunha Colombo Bonadio, Renata Rodrigues, Martins, Renata Eiras, Zuppani, Henrique Bortot, de Castro, Gilberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880229/ https://www.ncbi.nlm.nih.gov/pubmed/29662531 http://dx.doi.org/10.3332/ecancer.2018.818

Ejemplares similares

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
por: Harada, Guilherme, et al.
Publicado: (2019)

Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer
por: Lee, Kyung Ann, et al.
Publicado: (2014)

ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
por: Jiang, Jun, et al.
Publicado: (2022)

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement
por: Ijichi, Miharu, et al.
Publicado: (2022)

ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
por: Tsakonas, Georgios, et al.
Publicado: (2020)

Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports
por: Gozzi, Elisa, et al.
Publicado: (2020)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report
por: Chuang, Xin, et al.
Publicado: (2018)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
por: Bearz, Alessandra, et al.
Publicado: (2014)

Pretreatment Thoracic CT Radiomic Features to Predict Brain Metastases in Patients With ALK-Rearranged Non-Small Cell Lung Cancer
por: Wang, Hua, et al.
Publicado: (2022)

Correction: ALK inhibitors in ALK-rearranged nonsmall cell lung cancer with and without brain metastases: systematic review and network meta-analysis
Publicado: (2022)

Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review
por: Sasano, Hajime, et al.
Publicado: (2018)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
por: Mattsson, Johanna S. M., et al.
Publicado: (2016)

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
por: Zhao, Ruiying, et al.
Publicado: (2022)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Effectiveness and toxicity of adjuvant chemotherapy in patients with non-small cell lung cancer
por: Harada, Guilherme, et al.
Publicado: (2021)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy
por: Zhang, Ning-Ning, et al.
Publicado: (2014)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Oulhen, Marianne, et al.
Publicado: (2021)

Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung
por: Shi, Mingxia, et al.
Publicado: (2018)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

ALK-rearrangements and testing methods in non-small cell lung cancer: a review
por: Shackelford, Rodney E., et al.
Publicado: (2014)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
por: Pan, Yue, et al.
Publicado: (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer
por: Wang, Zizong, et al.
Publicado: (2022)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique
por: Nicoś, M., et al.
Publicado: (2017)

Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
por: Xing, Puyuan, et al.
Publicado: (2016)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
por: Hu, Han, et al.
Publicado: (2022)

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer
por: Sakashita, Takuya, et al.
Publicado: (2022)

ALK‐rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report
por: Xu, Yan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_69v2pqkaf0e3kneev8cgcuu7g7